We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-12.52%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.5B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
1.63%
Top 10 Hldgs %
41.52%
Holding
149
New
17
Increased
43
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$108M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$75.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$71.1M
4
LLY icon
Eli Lilly
LLY
+$70.2M
5
UNH icon
UnitedHealth
UNH
+$67.9M

Top Sells

Rank Stock Value
1
HNT
HEALTH NET INC
HNT
+$205M
2
VTRS icon
Viatris
VTRS
+$149M
3
AFFX
Affymetrix Inc
AFFX
+$75.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$59.4M
5
BMY icon
Bristol-Myers Squibb
BMY
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.92%
2 Financials 0.22%
3 Technology 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYNA
76
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$13.2M 0.14%
1,140,325
– –
BXLT
77
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$13.2M 0.14%
326,000
+41,000
+14% +$1.62M
EXAS
78
DELISTED
Exact Sciences
EXAS
$12.7M 0.13%
+1,890,400
New +$12.1M
CLVS
79
DELISTED
Clovis Oncology, Inc.
CLVS
$12.7M 0.13%
660,900
-68,700
-9% -$1.45M
EHTH icon
80
eHealth
EHTH
$42.2M
$12.2M 0.13%
1,300,000
– –
NTRA icon
81
Natera
NTRA
$35.8B
$12.1M 0.13%
1,276,190
– –
MCK icon
82
McKesson
MCK
$106B
$12.1M 0.13%
77,200
-272,172
-78% -$44M
NBRV
83
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$11.8M 0.12%
5,260
– –
JAZZ icon
84
Jazz Pharmaceuticals
JAZZ
$16.1B
$11.8M 0.12%
90,000
– –
ENSG icon
85
The Ensign Group
ENSG
$10.6B
$11.6M 0.12%
549,680
+20,311
+4% +$400K
PRQR icon
86
ProQR Therapeutics
PRQR
$243M
$11.3M 0.12%
2,305,446
+33,946
+1% +$173K
MRK icon
87
Merck
MRK
$325B
$11.1M 0.12%
+220,499
New +$10.8M
ZBH icon
88
Zimmer Biomet
ZBH
$18.7B
$11M 0.12%
106,090
-45,114
-30% -$4.36M
SRRA
89
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.9M 0.12%
40,579
-9,170
-18% -$2.93M
RCKT icon
90
Rocket Pharmaceuticals
RCKT
$334M
$10.3M 0.11%
347,750
+241,500
+227% +$7.25M
EW icon
91
Edwards Lifesciences
EW
$49.3B
$10.1M 0.11%
+345,000
New +$9.52M
SNDX icon
92
Syndax Pharmaceuticals
SNDX
$1.68B
$10.1M 0.11%
+757,365
New +$9.52M
ABT icon
93
Abbott
ABT
$191B
$9.91M 0.1%
237,000
+26,000
+12% +$1.03M
CLLS
94
Cellectis
CLLS
$287M
$9.63M 0.1%
350,000
– –
LKFT
95
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$9.62M 0.1%
230,000
– –
IMMU
96
DELISTED
Immunomedics Inc
IMMU
$9.51M 0.1%
3,802,000
– –
SIEN
97
DELISTED
Sientra, Inc.
SIEN
$9.29M 0.1%
135,750
– –
AET
98
DELISTED
Aetna Inc
AET
$8.54M 0.09%
76,000
+9,000
+13% +$963K
ITCI
99
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.17M 0.09%
+294,000
New +$9.8M
RARE icon
100
Ultragenyx Pharmaceutical
RARE
$2.5B
$8.12M 0.09%
+128,300
New +$8.4M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2016 Portfolio in Review

As of Q1 2016, OrbiMed held 149 positions worth $9.5B, down 14% from $11B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q1 2016 filing shows 17 new, 43 increased, 27 reduced and 8 closed positions. Its largest new stake was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M. The largest sale was HEALTH NET INC, an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q1 2016 buy was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M.
  • OrbiMed added most to Vertex Pharmaceuticals in Q1 2016, an estimated $108M increase.
  • OrbiMed's biggest Q1 2016 reduction was Viatris, cutting an estimated $149M.
  • OrbiMed fully exited HEALTH NET INC in Q1 2016, selling an estimated $205M.
  • OrbiMed's ten largest holdings make up 42% of its $9.5B portfolio in Q1 2016.
  • OrbiMed opened 17 new positions and closed 8 in Q1 2016.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $9.5B.

Based on OrbiMed's 13F filing for Q1 2016, filed 16 May 2016.